Cimzia meets REALISTIC endpoint

UCB Group (Euronext:UCB) said subcutaneous Cimzia certolizumab met the primary endpoint of significantly improving ACR20 response rate at week 12 vs. vs. placebo in the Phase IIIb REALISTIC trial to treat rheumatoid arthritis (51.1% vs. 25.9%, p<0.001). The double-blind, international trial enrolled 1,063 patients. Data were presented at the American College of Rheumatology meeting in Atlanta. Cimzia is approved in the EU and U.S. for RA and in the U.S. for Crohn's disease. UCB was off EUR 0.02 to EUR 27.98 on Tuesday. ...